Chronic kidney disease (CKD) is a key challenge for public health worldwide, and hypertension is one of the most prevalent cardiovascular risk factors for CKD. Traditionally, drug recommendations have been provided using methods of evidence-based medicine. The aim of our study is to recommend influential antihypertensive drugs for patients with CKD by mining the MEDLINE literature database.Design and Method:
A graph-based ranking algorithm was used to calculate the most influential antihypertensive drugs for CKD.Results:
Over an exhaustive study on all research literatures published in MEDLINE, Irbesartan is ranked as the most influential antihypertensive drug for patients with CKD in our study. The status of loop diuretics has lessened over time, and the importance of angiotensin receptor blockers has increased rapidly. The recommended antihypertensive drug categories determined by MedRank appeared prior to the release of hypertension guidelines. The concordance between physician rankings collected via questionnaires and our system output rankings was not high (average overlap, 0.53 ± 0.20); however, the concordance increased with increasing position of physicians (P < 0.05).Conclusions:
In conclusion, among patients with CKD, irbesartan was considered as the most influential antihypertensive drug by MedRank, which is a crucial method for determining antihypertensive drug recommendations for patients with CKD. This approach is a potential method for medical literature discovery, decision support, and guideline development.